Filana Therapeutics (FLNA) Appoints Jill M. Quigley to Its Board

Filana Therapeutics (FLNA) added Jill M. Quigley to its board. The company expects to start patient screening for its Phase 2a simufilam study in TSC-related epilepsy by Q1 2027, according to the company.

Original reporting
Published Nov 11, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Filana Therapeutics (FLNA) Appoints Jill M. Quigley to Its Board — source image
Decision brief

The 30-second read

$FLNANeutralLow
01

Why it matters

Board addition is a routine governance update with limited trading relevance.

02

Market read

Low relevance; no immediate price catalyst.

03

What to watch

Potential future clinical milestones (Phase 2a screening) may become more relevant than the appointment itself.

Relevance 4/10Novelty 2/10Timing: no immediate impact

Background

Filana Therapeutics is a clinical-stage biotech developing simufilam for TSC-related epilepsy.

Company-level read

Ticker impact

$FLNANeutralHigh confidence
Context

Board appointment of Jill M. Quigley announced, indicating governance change.

Expected impact

likely little price movement as board changes are typically low impact.

Evidence & confidence

Board appointments rarely move the stock unless tied to strategic shift; no new catalyst beyond the appointment.

Market effects

None significant; biotech sector unchanged.

None.

None.

Counterpoint

If investors view board changes as a signal of upcoming strategic moves, the stock could see modest upside.

Key entities

  • Filana Therapeutics

    Clinical-stage biotech developing simufilam.

  • Jill M. Quigley

    New board member.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing